Zealand Pharma Announces First Participant Enrolled in ZUPREME-1 Phase 2b Trial
Zealand Pharma has enrolled the first participant in its ZUPREME-1 Phase 2b trial, focusing on the effects of petrelintide on body weight, safety, and tolerability in individuals with obesity or overweight and weight-related co-morbidities.